---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-23-000027"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T06:08:49.218634+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amneal Q2 revenue up 7% to $599M, net income $12M; raises 2023 guidance

## Summary
- Q2 net revenue $599M, +7% YoY; GAAP net income $12M vs loss $121M prior year.
- Adjusted net income $57M, adjusted EBITDA $146M (+9% YoY), adjusted diluted EPS $0.19.
- Raising 2023 full year guidance following strong H1 performance.
- Growth driven by Generics (complex portfolio, biosimilars), AvKARE expansion, and Specialty.
- Company addressing U.S. drug shortages as one of largest domestic manufacturers.

## SEC filing metadata
- accession: 0001723128-23-000027
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000027/0001723128-23-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000027/amrx-20230804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-23-000027
- JSON: https://secwatch.observer/filing/0001723128-23-000027.json
- Plain text: https://secwatch.observer/filing/0001723128-23-000027.txt

## Key facts
- Earnings Releases
  Amneal Pharmaceuticals, Inc. reported second quarter ended June 30, 2023 results: revenue $599 million, net income $12 million, EPS $0.08. Guidance raised.
  - Period: second quarter ended June 30, 2023
  - Revenue: $599 million
  - Net income: $12 million
  - EPS: $0.08
  - Guidance: raised
  - Result: reported results
  source text: AMNEAL REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS ‒ Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 ‒ ‒ Q2 2023 Adjusted Net Income (1) of $57 million; Adjusted EBITDA (1) of $146 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Raising 2023 Full Year Guidance ‒
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000027/0001723128-23-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.